• 100% of the 42 studies to date report positive effects. Random effects meta-analysis for early treatment and pooled effects shows a reduction of 83%, RR 0.17 [0.11-0.28]. Prophylactic use shows a reduction of 89%, RR 0.11 [0.05-0.23]. Mortality results show 75% lower mortality, RR 0.25 [0.14-0.44] for all treatment delays, and 86% lower, RR 0.14 [0.03-0.62] for early treatment.
• 100% of the 21 Randomized Controlled Trials (RCTs) report positive effects, with an estimated reduction of 70%, RR 0.30 [0.19-0.49].
• The probability that an ineffective treatment generated results as positive as the 42 studies to date is estimated to be 1 in 4 trillion (
p = 0.00000000000023).
Early treatment | 83% improvement | RR 0.17 [0.11-0.28] |
Late treatment | 51% improvement | RR 0.49 [0.37-0.66] |
Prophylaxis | 89% improvement | RR 0.11 [0.05-0.23] |
Total | 42 studies | 331 authors | 14,906 patients |
RCT | 21 studies | 180 authors | 2,869 patients |
Indication | Studies | Patients | Effect size | WHO status |
Scabies [Kory] | 6 | 613 | 0.65 [0.54‑0.78]35% improvement | Approved |
COVID-19 (RCT) | 21 | 2,869 | 0.30 [0.19‑0.49] 70% improvement | Not approved yet |
COVID-19 (all) | 42 | 14,906 | 0.25 [0.19‑0.34] 75% improvement |
Covid Analysis et al., 2/23/2021, preprint, 1 author.